Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed the day trading at $42.31 up 5.01% from the previous closing price of $40.29. In other words, the price has increased by $5.01 from its previous closing price. On the day, 2.26 million shares were traded. ARWR stock price reached its highest trading level at $43.24 during the session, while it also had its lowest trading level at $39.6985.
Ratios:
For a better understanding of ARWR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.87 and its Current Ratio is at 4.87. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Hamilton James C sold 20,000 shares for $35.00 per share. The transaction valued at 700,000 led to the insider holds 212,122 shares of the business.
James Hamilton bought 20,000 shares of ARWR for $700,015 on Oct 01 ’25. On Sep 12 ’25, another insider, Hamilton James C, who serves as the Chief Medical Officer of the company, sold 15,000 shares for $30.00 each. As a result, the insider received 450,000 and left with 232,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 5849677312 and an Enterprise Value of 5662283776. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.21 while its Price-to-Book (P/B) ratio in mrq is 11.19. Its current Enterprise Value per Revenue stands at 9.882 whereas that against EBITDA is -66.306.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.28, which has changed by 1.170857 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $40.75, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 31.49%, while the 200-Day Moving Average is calculated to be 108.47%.
Shares Statistics:
Over the past 3-months, ARWR traded about 2.34M shares per day on average, while over the past 10 days, ARWR traded about 1662900 shares per day. A total of 138.14M shares are outstanding, with a floating share count of 128.36M. Insiders hold about 7.16% of the company’s shares, while institutions hold 75.34% stake in the company. Shares short for ARWR as of 1760486400 were 11648427 with a Short Ratio of 4.97, compared to 1757894400 on 11862693. Therefore, it implies a Short% of Shares Outstanding of 11648427 and a Short% of Float of 10.870000000000001.
Earnings Estimates
. The current rating of Arrowhead Pharmaceuticals Inc (ARWR) is the result of assessments by 11.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.33, with high estimates of $2.0 and low estimates of -$1.14.
Analysts are recommending an EPS of between $0.82 and -$1.06 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$2.89, with 11.0 analysts recommending between -$0.85 and -$5.01.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $244.29M. There is a high estimate of $468.84M for the next quarter, whereas the lowest estimate is $23M.
A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $923M, while the lowest revenue estimate was $573M, resulting in an average revenue estimate of $730.73M. In the same quarter a year ago, actual revenue was $3.55MBased on 14 analysts’ estimates, the company’s revenue will be $390.32M in the next fiscal year. The high estimate is $646.8M and the low estimate is $90M.
